110 related articles for article (PubMed ID: 32229417)
1. Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.
Kilpeläinen TP; Talala K; Taari K; Raitanen J; Kujala P; Pylväläinen J; Tammela TL; Auvinen A
Eur J Cancer; 2020 May; 130():204-210. PubMed ID: 32229417
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
Joentausta RM; Rannikko A; Murtola TJ
Prostate; 2019 May; 79(6):583-591. PubMed ID: 30652328
[TBL] [Abstract][Full Text] [Related]
3. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
[TBL] [Abstract][Full Text] [Related]
4. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer outcomes for men who present with symptoms at diagnosis.
Beckmann KR; O'Callaghan ME; Ruseckaite R; Kinnear N; Miller C; Evans S; Roder DM; Moretti K;
BJU Int; 2017 Jun; 119(6):862-871. PubMed ID: 27489140
[TBL] [Abstract][Full Text] [Related]
6. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
7. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
8. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
Seikkula HA; Kaipia AJ; Ryynänen H; Seppä K; Pitkäniemi JM; Malila NK; Boström PJ
Int J Cancer; 2018 Mar; 142(5):891-898. PubMed ID: 29044563
[TBL] [Abstract][Full Text] [Related]
9. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
10. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
12. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
[TBL] [Abstract][Full Text] [Related]
13. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study.
Pettersson A; Robinson D; Garmo H; Holmberg L; Stattin P
Ann Oncol; 2018 Feb; 29(2):377-385. PubMed ID: 29161337
[TBL] [Abstract][Full Text] [Related]
14. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer.
Kilpeläinen TP; Talala K; Raitanen J; Taari K; Kujala P; Tammela TLJ; Auvinen A
Am J Epidemiol; 2016 Nov; 184(10):720-731. PubMed ID: 27777219
[TBL] [Abstract][Full Text] [Related]
16. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
17. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation.
Feldman AS; Meyer CP; Sanchez A; Krasnova A; Reznor G; Menon M; Kibel AS; Choueiri TK; Lipsitz SR; Sun M; Trinh QD
J Urol; 2017 Nov; 198(5):1061-1068. PubMed ID: 28552709
[TBL] [Abstract][Full Text] [Related]
18. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
19. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA.
Seikkula HA; Kaipia AJ; Rantanen ME; Pitkäniemi JM; Malila NK; Boström PJ
Acta Oncol; 2017 Jul; 56(7):971-977. PubMed ID: 28406044
[TBL] [Abstract][Full Text] [Related]
20. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
